Regeneron Pharmaceuticals Inc. (REGN) Stock News
Follow the latest Regeneron Pharmaceuticals Inc. (REGN) news and market headlines alongside the live REGN price. Stay informed on what's moving REGN.
News
Read Full Article Read Full Article - Read Full Article
Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
- Read Full Article
Regeneron Pharmaceuticals Says EC Approves Alternative, Flexible Dosing Schedule For Libtayo Across All Approved Skin, Lung And Cervical Cancer Indications
Approval introduces an extended dosing regimen of Libtayo 700 mg given every six weeks, following initial 12 weeks of treatment with Libtayo 350 mg every three weeksAlso approved is an option of reducing subsequent
- Read Full Article
Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study
Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.
Read Full Article - Read Full Article
If You Invested $1000 In Regeneron Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 8.79% on an annualized basis producing an average annual return of 21.73%. Currently, Regeneron Pharmaceuticals has a market
- Read Full Article
BCMA Targeted Therapies Competitive Landscape Analysis: 100+ Pipeline Therapies Driving Innovation in Therapeutics Segment | DelveInsight
DelveInsight released a comprehensive competitive landscape report on BCMA-targeted therapies, analyzing 100+ pipeline drugs across 80+ companies. The report highlights recent clinical advances including Pfizer's positive Phase III results for ELREXFIO, AbbVie's BLA submission for etentamig, and Gilead's $7.8 billion acquisition of Arcellx to gain control of anito-cel. Key challenges include treatment resistance, relapse, and manufacturing complexity, while the pipeline focuses on improving durability, safety, and accessibility through next-generation approaches.
- Read Full Article
REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock?
Regeneron Pharmaceuticals (REGN) shares surged 27.4% over the past month, driven by strong third-quarter results. Eylea HD sales jumped 62% to $699 million, offsetting declining Eylea sales amid competition from Roche's Vabysmo. Strong Dupixent profits, oncology portfolio expansion, and a promising pipeline including cemdisiran for myasthenia gravis support long-term growth. The stock trades at an attractive valuation of 13.29X forward earnings, below historical and industry averages, earning a Zacks Rank #2 (Buy) rating.
Explore More US Stocks
Data Sources and Disclosures
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to REGN, including RealStocks and Stock Futures.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.
